Initial Statement of Beneficial Ownership (3)
February 14 2020 - 6:39PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Burkhardt Glen |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/12/2020
|
3. Issuer Name and Ticker or Trading Symbol
PhaseBio Pharmaceuticals Inc [PHAS]
|
(Last)
(First)
(Middle)
C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) VP, Human Resources / |
(Street)
MALVERN, PA 19355
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (right to buy) | (1) | 3/16/2029 | Common Stock | 36000.0 | $3.72 | D | |
Explanation of Responses: |
(1) | One-fourth (1/4th) of the shares vest one year after the grant date; the balance of the shares shall vest in a series of 36 successive equal monthly installments measured from the first anniversary of the grant date, subject to the Reporting Person's continuous service as of each such date. |
Remarks: Exhibit List - Exhibit 24 - Power of Attorney |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Burkhardt Glen C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN, PA 19355 |
|
| VP, Human Resources |
|
Signatures
|
/s/ John Sharp, Attorney-in-fact | | 2/14/2020 |
**Signature of Reporting Person | Date |
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Aug 2024 to Sep 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Sep 2023 to Sep 2024